← Back to Search

Cognitive Behavioral Therapy

Siempre Seguiré for HIV/AIDS

N/A
Waitlist Available
Led By Laura Bogart, PhD
Research Sponsored by RAND
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Biologically male at birth and continue to identify as male
Identify as Latino
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-5 and 6-7 months post-baseline
Awards & highlights

Study Summary

This trial will test a cognitive behavior therapy group intervention designed to help Latino men who have sex with men living with HIV to cope with discrimination and adhere to their antiretroviral treatment.

Eligible Conditions
  • HIV/AIDS

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You were born male and still identify as male.
Select...
You self-identify as a person of Latin American descent.
Select...
You have had sex with a man within the last 12 months.
Select...
You are taking medication for HIV/AIDS (ART).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-5 and 6-7 months post-baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-5 and 6-7 months post-baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Continuous Adherence (MEMS)
Continuous Adherence (Self-report)
Secondary outcome measures
Dysfunctional Coping Strategies
Functional Coping Strategies
Internalized Stigma (HIV)
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Siempre SeguiréExperimental Treatment1 Intervention
We will conduct a small randomized controlled trial (RCT), testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
Group II: ControlActive Control1 Intervention
Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Siempre Seguiré
2018
N/A
~90

Find a Location

Who is running the clinical trial?

RANDLead Sponsor
137 Previous Clinical Trials
510,169 Total Patients Enrolled
Bienestar Human Services, Inc.OTHER
3 Previous Clinical Trials
597 Total Patients Enrolled
Laura Bogart, PhDPrincipal InvestigatorRAND
5 Previous Clinical Trials
1,298 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment in this experiment still open?

"Based on the clinicaltrials.gov listing, this research protocol is not presently accepting participants. It was initially posted in March 2018 and last edited in January 2022; however, there are currently 251 other trials actively recruiting patients."

Answered by AI

What outcomes is this research aiming to demonstrate?

"The primary evaluation of this trial is Continuous Adherence (Self-report) over a 4 to 7 month post baseline period. Secondary assessments are Negative Religious Coping Strategies, Medical Mistrust (HIV Conspiracy Beliefs), and Internalized Stigma (Sexual Orientation). All measurements use numerical scales ranging from ‘Strongly Disagree’ to ‘Strongly Agree'."

Answered by AI
~12 spots leftby Mar 2025